According to a report on global health business trends published by the Korea Health Industry Development Institute, clinical trials utilizing cutting-edge digital technologies are expected to gain momentum in 2023. The decentralization of clinical trials (DCT) has emerged as a strategic measure to advance the pharmaceutical and healthcare industry, becoming a key focus area following the challenges posed by the pandemic.
In this context, two leading companies in the domestic clinical data management solutions sector are attracting attention with their contrasting strategies: one focusing on integration and the other on vertical specialization.
▲ JNPMEDI: Focusing on Core Competencies with a Vertical Strategy
JNPMEDI (CEO Kwunho Jeong) is taking a path that emphasizes strengthening its core services. The company plans to lead the digital transformation of clinical trials by prioritizing customer value and pursuing a vertical strategy centered on its core competencies. JNPMEDI aims to become a specialized data platform company that not only covers clinical trials but also extends to the broader medical field, leveraging advanced technology and fostering collaborations with related companies both domestically and internationally.
Through its Maven CDMS (Clinical Data Management System), JNPMEDI provides clinical trial data collection and analysis services. The product is gaining market traction due to its functional advantages and cost-effectiveness compared to existing clinical solutions. The company is also focusing on enhancing service competitiveness through unique technological capabilities such as blockchain-based data protection, the convenience of SaaS (Software as a Service), and flexible integration with various digital devices.
Recently, JNPMEDI has garnered attention in the industry by launching the Maven DCT Suite to address the burgeoning DCT market post-pandemic. Additionally, it introduced Maven Docs, the country's first clinical trial document creation and management solution.
Moving forward, JNPMEDI plans to continue its focus on digitalizing clinical trials by launching new services, including online recruitment of clinical trial participants and management of adverse drug reaction data, aiming to position itself as a service-oriented company specializing in clinical trial digitalization.
According to a report on global health business trends published by the Korea Health Industry Development Institute, clinical trials utilizing cutting-edge digital technologies are expected to gain momentum in 2023. The decentralization of clinical trials (DCT) has emerged as a strategic measure to advance the pharmaceutical and healthcare industry, becoming a key focus area following the challenges posed by the pandemic.
In this context, two leading companies in the domestic clinical data management solutions sector are attracting attention with their contrasting strategies: one focusing on integration and the other on vertical specialization.
▲ JNPMEDI: Focusing on Core Competencies with a Vertical Strategy
JNPMEDI (CEO Kwunho Jeong) is taking a path that emphasizes strengthening its core services. The company plans to lead the digital transformation of clinical trials by prioritizing customer value and pursuing a vertical strategy centered on its core competencies. JNPMEDI aims to become a specialized data platform company that not only covers clinical trials but also extends to the broader medical field, leveraging advanced technology and fostering collaborations with related companies both domestically and internationally.
Through its Maven CDMS (Clinical Data Management System), JNPMEDI provides clinical trial data collection and analysis services. The product is gaining market traction due to its functional advantages and cost-effectiveness compared to existing clinical solutions. The company is also focusing on enhancing service competitiveness through unique technological capabilities such as blockchain-based data protection, the convenience of SaaS (Software as a Service), and flexible integration with various digital devices.
Recently, JNPMEDI has garnered attention in the industry by launching the Maven DCT Suite to address the burgeoning DCT market post-pandemic. Additionally, it introduced Maven Docs, the country's first clinical trial document creation and management solution.
Moving forward, JNPMEDI plans to continue its focus on digitalizing clinical trials by launching new services, including online recruitment of clinical trial participants and management of adverse drug reaction data, aiming to position itself as a service-oriented company specializing in clinical trial digitalization.